Chrysoeriol
Based on 6 publication(s) in Google Scholar
Chrysoeriol is a kind of natural yellow ash, which can be used for heating plants Coronopus didymus. Chrysoeriol suppresses the JAK2/STAT3, IκB/p65, and NF-κB pathways, and has strong anti-inflammatory activity.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 491-71-4
- Formula: C16H12O6
- Molecular Weight:300.26
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Chrysoeriol
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BXPC-3 | GI50 |
2.6 μg/mL
Compound: 5
|
Cytotoxicity against human BxPC3 cells after 48 hrs by SRB assay
Cytotoxicity against human BxPC3 cells after 48 hrs by SRB assay
|
[PMID: 12608861] |
| DU-145 | GI50 |
1.1 μg/mL
Compound: 5
|
Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
|
[PMID: 12608861] |
| KM-20L2 | GI50 |
2.5 μg/mL
Compound: 5
|
Cytotoxicity against human KM20L2 cells after 48 hrs by SRB assay
Cytotoxicity against human KM20L2 cells after 48 hrs by SRB assay
|
[PMID: 12608861] |
| MCF7 | GI50 |
3.1 μg/mL
Compound: 5
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 12608861] |
| Monocyte | IC50 |
22 μM
Compound: Chrysoeriol
|
Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA
Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA
|
[PMID: 10096854] |
| Monocyte | IC50 |
2.6 μM
Compound: chrysoeriol
|
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
|
[PMID: 8882428] |
| Monocyte | IC50 |
2.6 x 10-6 M
Compound: chrysoeriol
|
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
|
[PMID: 8882428] |
| NCI-H460 | GI50 |
2.1 μg/mL
Compound: 5
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay
|
[PMID: 12608861] |
| Neutrophil | IC50 |
0.4 μM
Compound: 4f, Chrysoeriol
|
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay
|
[PMID: 23871908] |
| Neutrophil | IC50 |
2.8 μM
Compound: 4f, Chrysoeriol
|
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay
|
[PMID: 23871908] |
| Neutrophil | IC50 |
7.1 μM
Compound: 4f, Chrysoeriol
|
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay
|
[PMID: 23871908] |
| Neutrophil | IC50 |
8.6 μM
Compound: 4f, Chrysoeriol
|
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay
|
[PMID: 23871908] |
| P388 | GI50 |
4 μg/mL
Compound: 5
|
Cytotoxicity against mouse P388 cells after 48 hrs by SRB assay
Cytotoxicity against mouse P388 cells after 48 hrs by SRB assay
|
[PMID: 12608861] |
| Platelet | IC50 |
27.14 μM
Compound: 5
|
Anti-platelet activity in rat platelet rich plasma assessed as inhibition of ADP and calcium-induced platelet aggregation incubated at 37 degC for 10 mins and measured 30 mins after ADP and calcium addition
Anti-platelet activity in rat platelet rich plasma assessed as inhibition of ADP and calcium-induced platelet aggregation incubated at 37 degC for 10 mins and measured 30 mins after ADP and calcium addition
|
[PMID: 26096681] |
| RAW264.7 | IC50 |
14.2 μM
Compound: 7
|
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method
|
[PMID: 19778086] |
| RAW264.7 | IC50 |
0.24 μM
Compound: 7
|
Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method
Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method
|
[PMID: 25176187] |
| RAW264.7 | IC50 |
3.1 μM
Compound: 44
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as suppression of LPS-induced iNOS expression preincubated with compound for 1 hrs followed by LPS-stimulation and measured after 24 hrs by Western blot analysis
Antiinflammatory activity in mouse RAW264.7 cells assessed as suppression of LPS-induced iNOS expression preincubated with compound for 1 hrs followed by LPS-stimulation and measured after 24 hrs by Western blot analysis
|
[PMID: 37683361] |
| SF-268 | GI50 |
1.7 μg/mL
Compound: 5
|
Cytotoxicity against human SF268 cells after 48 hrs by SRB assay
Cytotoxicity against human SF268 cells after 48 hrs by SRB assay
|
[PMID: 12608861] |
Chrysoeriol (5 μM, 10 μM or 20 μM; 24 h) exert a neuroprotective effect in the MPP--triggered cytotoxicity and apoptosis in SH-SY5Y cells[2].
Chrysoeriol (20 μM; 24 h) inhibits the production of NO and PGE2 in LPS-stimulated RAW 264.7 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 491-71-4
-
Appearance Solid
-
Molecular Weight 300.26
-
Formula C16H12O6
-
Color Light yellow to yellow
-
SMILES
O=C1C=C(C2=CC=C(O)C(OC)=C2)OC3=CC(O)=CC(O)=C13
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Food Funct
Polyphenol-rich extract from Torreya grandis peel attenuates lipopolysaccharide-induced inflammation in RAW264.7 macrophages via inhibition of the TLR4/NF-κB pathway. [Abstract]2025 Sep 26. PMID: 41002170 -
Int J Mol Sci
Elucidating the Mechanisms of Chrysanthemum Action on Atopic Dermatitis via Network Pharmacology and Machine Learning. [Abstract]2025 Nov 21;26(23):11262. PMID: 41373428 -
-
Naunyn Schmiedebergs Arch Pharmacol
Network pharmacology and experimental validation to explore the effects and mechanisms of flavonoids luteolin and chrysoeriol against non‑small cell lung cancer. [Abstract]2026 Jan 28. PMID: 41603923 -
Naunyn Schmiedebergs Arch Pharmacol
Chrysoeriol: a natural RANKL inhibitor targeting osteoclastogenesis and ROS regulation for osteoporosis therapy. [Abstract]2025 Jun;398(6):7389-7407. PMID: 39755833 -
Solvent & Solubility
DMSO : 100 mg/mL (333.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.33 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (8.33 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Beena Mishra, et al. Effect of O-glycosilation on the Antioxidant Activity and Free Radical Reactions of a Plant Flavonoid, Chrysoeriol. Bioorg Med Chem. 2003 Jul 3;11(13):2677-85. [Content Brief]
[2]. Limboonreung T, et al. Chrysoeriol mediates mitochondrial protection via PI3K/Akt pathway in MPP+ treated SH-SY5Y cells. Neurosci Lett. 2020 Jan 1;714:134545. [Content Brief]
[3]. Wu JY, et al. Chrysoeriol ameliorates TPA-induced acute skin inflammation in mice and inhibits NF-κB and STAT3 pathways. Phytomedicine. 2020 Mar;68:153173. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3304 mL | 16.6522 mL | 33.3045 mL | 83.2612 mL |
| 5 mM | 0.6661 mL | 3.3304 mL | 6.6609 mL | 16.6522 mL | |
| 10 mM | 0.3330 mL | 1.6652 mL | 3.3304 mL | 8.3261 mL | |
| 15 mM | 0.2220 mL | 1.1101 mL | 2.2203 mL | 5.5507 mL | |
| 20 mM | 0.1665 mL | 0.8326 mL | 1.6652 mL | 4.1631 mL | |
| 25 mM | 0.1332 mL | 0.6661 mL | 1.3322 mL | 3.3304 mL | |
| 30 mM | 0.1110 mL | 0.5551 mL | 1.1101 mL | 2.7754 mL | |
| 40 mM | 0.0833 mL | 0.4163 mL | 0.8326 mL | 2.0815 mL | |
| 50 mM | 0.0666 mL | 0.3330 mL | 0.6661 mL | 1.6652 mL | |
| 60 mM | 0.0555 mL | 0.2775 mL | 0.5551 mL | 1.3877 mL | |
| 80 mM | 0.0416 mL | 0.2082 mL | 0.4163 mL | 1.0408 mL | |
| 100 mM | 0.0333 mL | 0.1665 mL | 0.3330 mL | 0.8326 mL |